Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Operating Leases (2019 - 2025)

IDEAYA Biosciences' Operating Leases history spans 7 years, with the latest figure at $27.6 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 46.11% year-over-year to $27.6 million; the TTM value through Dec 2025 reached $27.6 million, up 46.11%, while the annual FY2025 figure was $27.6 million, 46.11% up from the prior year.
  • Operating Leases for Q4 2025 was $27.6 million at IDEAYA Biosciences, up from $26.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $27.6 million in Q4 2025 and bottomed at $611000.0 in Q2 2023.
  • The 5-year median for Operating Leases is $3.5 million (2021), against an average of $9.3 million.
  • The largest annual shift saw Operating Leases crashed 76.24% in 2023 before it soared 1942.99% in 2025.
  • A 5-year view of Operating Leases shows it stood at $3.5 million in 2021, then plummeted by 53.73% to $1.6 million in 2022, then tumbled by 30.17% to $1.1 million in 2023, then skyrocketed by 1577.6% to $18.9 million in 2024, then skyrocketed by 46.11% to $27.6 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Operating Leases are $27.6 million (Q4 2025), $26.9 million (Q3 2025), and $26.3 million (Q2 2025).